Clinical Trial Update: Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Technosphere insulin inhalation powder (Afrezza) to rapid-acting insulin in adults with Type 2 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)
• Rapid-acting insulin

Snippet

Sponsor: Mannkind Corporation | Conditions: Diabetes Type 2 | Phase 3 | Status: COMPLETED